Medical devices, healthcare technology and the business of care
510(k) clearance · K251721

Xpert GI Panel

Cepheid · Decision date Jan 16, 2026

FDA DECISIONK251721

What did the FDA decide?

FDA records K251721 as a 510(k) premarket notification, with a decision dated Jan 16, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Jan 16, 2026

FDA source record

Regulatory record facts

Identifier
K251721
Regulatory pathway
510(k) premarket notification
Applicant
Cepheid
Product code
PCH
Decision code
SESE
Decision date
Jan 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System.

Applicant
Cepheid
Product code
PCH
FDA device class
2

FDA decision timeline

  1. K251721 received

    Application receipt date recorded by FDA.

  2. K251721 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code PCH

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cepheid

Headquarters
Not reported
Brand website
cepheid.com
FDA applicant address
Sunnyvale, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records